Life sciences briefing: Monday, Aug. 6, 2007
(UPDATED at 5:05 p.m. PDT; see below.)
(As part of my ongoing effort to strike the right balance between keeping up with venture-business news and writing more analysis, I’m inaugurating a daily briefing that will collect deal-related news items from the life sciences in one place. I’ll… Continue Reading
IPO roundup: Sucampo prices low, Amedica’s IPO withdrawn
One deal down – Sucampo Pharmaceuticals, which had filed to raise as much as $69 million in its IPO (we covered them briefly here), priced its IPO well below expectations. Although the company had planned to sell shares for $14 to $16 apiece, it ended up… Continue Reading
Genoptix files $86M IPO for diagnostic services
Genoptix, a Carlsbad, Calif., provider of diagnostic services to cancer and blood-disease specialists, filed to raise as much as $86.25 million in an intial offering. The company specializes in genetic and other testing of blood and bone-marrow samples in order to diagnose various cancers and… Continue Reading
Talecris, a ludicrously large IPO, and the beginning of the end for private equity?
(UPDATED: See below.) Is the air starting to hiss out of the private-equity bubbble? Looking at Talecris Biotherapeutics, a stodgy biotech controlled by private-equity firms Cerberus Capital Management and Ampersand Ventures that filed to raise as much as $1 billion in an initial offering last Friday, you’d… Continue Reading
Funding roundup: Announcements that got away
Although I try to stay on top of events in the life sciences, announcements do sometimes manage to slip through the cracks. Some days, in fact, I end up triaging. Because the roots of this site — not to mention many of its readers —… Continue Reading
Biotech financing: Will ImaRx break the IPO slump?
(UPDATED: See below.)
It’s been a long, barren summer for biotech IPOs, but ImaRx, the blood-clot company we featured here, finally managed to bull its way into the public markets. The company, which withdrew an earlier $75 million IPO and lowered its offering price on the current… Continue Reading
Aptamer-drug maker Archemix files for $69M IPO
(UPDATED: See below.)
Masimo: A patient-sensor specialist with a quarter-billion dollar IPO
(UPDATED: See below.)
Masimo, an Irvine, Calif., maker of non-invasive patient-monitoring products, expects to raise nearly a quarter-billion dollars in an IPO. (The company’s latest filing statement is here.) That IPO take is almost $100 billion higher than Masimo first proposed when it filed the offering on… Continue Reading
ImaRx: A blood-clot attacker with sinking IPO hopes
ImaRx, a Tuscon, Ariz., biotech developing new ways to dissolve blood clots in the lungs, lowered its IPO sights and now expects to raise no more than $17.3 million in the offering. (Its latest SEC filing is here.) Late last month, the company had hoped… Continue Reading
Amedica sets IPO terms, looks to raise $80.2M for implants
Amedica, a Salt Lake City device maker focused on spine, knee and hip implants, set its IPO terms and now hopes to raise as much as $80.2 million. The company plans to sell up to 5.3 million shares at a price of $13 to $15… Continue Reading
Bioheart: A risky stem-cell company boosts its IPO hopes
(UPDATED: See below.)
Sunrise, Fla.-based Bioheart thinks enough of its stem-cell treatment for heart disease that it has just boosted its expected IPO take by $10 million, to $45 million. A close reading of its latest SEC filing, however, raises a fair number of questions for would-be… Continue Reading
Virtual Radiologic, outsourced radiology company, seeks $75M IPO
Virtual Radiologic, a Minnetonka, Minn., provider of outsourced radiology services, hopes to raise $75 million in an initial offering. The company calls itself the second-largest provider of such “teleradiology” services, in which a dispersed network of radiology specialists read and interpret X-rays, MRIs and other… Continue Reading
Quark Pharma IPO delayed
Quark Pharmaceuticals, the biotech chameleon I profiled here, delayed an IPO that the company expects to raise as much as $81 million, VentureWire reports (subscription required). The newswire said the Fremont, Calif., developer of RNA-interference drugs was slated to begin trading on the Nasdaq Stock… Continue Reading
Athenahealth files for $86M IPO
Athenahealth, a Watertown, Mass., maker of health IT systems for billing and management of electronic health records, filed to raise as much as $86.25 million in an initial offering. The company’s SEC filing is here.
Athenahealth’s systems work as Web-based services, a strategy designed to take… Continue Reading
MAP Pharma charts course for $86M IPO
MAP Pharmaceuticals, a Mountain View, Calif., developer of reformulated drugs for inhalation, filed to raise up to $86 million in an initial public offering. The company’s registration statement with the SEC is here.
MAP is the latest drugmaker to brave the IPO waters, which have been… Continue Reading